[Monitoring and precautions to take during treatment with a biological immunomodulator].
Sibilia
J
J
Service de rhumatologie, Centre national de références des maladies auto-immunes systémiques, hôpital de Hautepierre, CHU de Strasbourg, avenue Molière, 67098 Strasbourg cedex, France. Jean.Sibilia@chru-strasbourg.fr
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods; D000075202:Contraindications; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab
Surveillance et précautions à prendre lors d'un traitement par un immunomodulateur biologique.